In the pivotal phase of the admIRE trial, the VARIPULSE™ Platform demonstrated 85% peak primary effectiveness with minimal adverse events, short PFA application times, and low fluoroscopy exposure Additional findings presented at HRS show the potential of the VARIPULSE™ Platform in…